Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse
- Adcytherix reinforces its Executive Committee with two pivotal appointments: CMO and CFO
- The ADCX – Engine is operational to start driving execution
Adcytherix SAS, a biopharmaceutical company pioneering next-generation proprietary antibody-drug conjugates (ADCs), today announced that it has finalized the setup of its ADCX – Engine, integrating next-generation payloads, and strengthened its executive team with the appointments of Jan H.M. Schellens, MD, PhD, as Chief Medical Officer and Jaime Arango, MBA, as Chief Financial Officer, to deliver on its ambitious strategy.
ADCX – Engine Ready to Deliver
At the core of Adcytherix’s strategy lies the ADCX – Engine, a proprietary approach integrating approved and clinically validated cancer drugs as payloads, using optimized, state-of-the-art linker architectures as well as precision antibody engineering. The ADCX-Engine enables the rational design of highly selective ADCs with fine-tuned conjugation parameters that extend beyond conventional payload classes, enhance stability, overcome resistance, and improve safety while achieving deeper, more durable anti-tumor responses across diverse cancer indications.
Strengthening the executive management team
The company also welcomes Jan H.M. Schellens, MD, PhD, as Chief Medical Officer (CMO) and Jaime Arango, MBA, as Chief Financial Officer (CFO), both joining the executive leadership team. These appointments reinforce Adcytherix’s position as a leader in ADC innovation and mark a key milestone in its transition from early-stage build-up to full execution. Both executives bring extensive experience and expertise, complementing the strong capabilities already in place, and further strengthening Adcytherix’s competencies in clinical development, translational oncology, and strategic finance.
Jack Elands, Chief Executive Officer of Adcytherix commented “the arrivals of Jan and Jaime strengthen our ability to translate our scientific breakthroughs into clinical value. Together, we are entering the phase of ADC development, delivering on the promise of novel ADCs using validated payloads with differentiated mechanisms of action focusing on patients who have developed resistance against today’s commonly used payloads. In addition to internal development, we are pursuing collaborative opportunities to bring new products to market faster and more effectively.”
“Adcytherix has established an exceptional foundation for translating science into patient benefit,” said Jan H.M. Schellens, MD, PhD, Chief Medical Officer. “I’m thrilled to lead the clinical development strategy as we advance ADCX-020 into first-in-human studies and advance the broader pipeline of innovative candidates into the clinic. My goal is to ensure that the design and execution of our first clinical programs fully reflect the transformative potential of the ADCX – Engine to deliver safer, more effective ADCs that truly redefine outcomes for patients with hard-to-treat cancers.”
“I’m excited to join Adcytherix at this pivotal moment, as the company transitions from start-up to execution,” said Jaime Arango, MBA, Chief Financial Officer. “With a robust financial foundation and strong investor backing, we are well positioned to accelerate our programs and deliver on our long-term value-creation strategy.”
Execution Roadmap
Following its €105 million Series A financing in 2025, Adcytherix has completed the build-out of its R&D infrastructure and expanded its scientific and management teams. Over the next few months, the team will focus on key execution milestones to become a clinical stage biopharmaceutical company with ADCX-020 and prepare the clinical entry for other proprietary and innovative ADCX programs.
